Clinical Trials Browser

OTHER × Carcinoma, Non-Small-Cell Lung × Afatinib × Clear all

NCT05215548 2025-02-19

Primary Tumor Resection With EGFR TKI for Stage IV NSCLC

Phase 2 Active not recruiting

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT06071013 2025-01-23

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT02364609 2024-10-16

Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib

Phase 1 Completed

11 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT06486142 2024-07-03

ERIS

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT01542437 2024-02-06

NSCLC

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT02795156 2023-12-05

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Phase 2 Completed

100 enrolled 14 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT02183883 2023-11-29

DARWIN1

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT03727724 2023-10-18

AFACET

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT03574402 2022-12-06

TRUMP

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02716311 2022-08-11

ACE-Lung

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03054038 2022-04-14

Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT01999985 2020-11-27

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

25 enrolled 10 charts

Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Pleural Diseases, Pleural Effusion, Pleural Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Pleural Effusion, Malignant

NCT01746251 2020-07-07

Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Carcinoma, Non-Small-Cell Lung

NCT02271906 2019-04-30

The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting

Phase 2 Terminated

2 enrolled 8 charts

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT01415011 2019-01-15

TIMELY

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT01074177 2018-03-09

Understanding Mechanisms of Acquired Resistance to BIBW2992

Phase NA Completed

24 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT01836341 2013-12-19

Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation

Phase 1 Withdrawn

Carcinoma, Non-Small-Cell Lung